TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AMGN

Amgen Inc

Healthcare · Drug Manufacturers - General

410.90$ +1.5% vs. previous close Closing price · As of: 7. Aug 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Amgen Inc (AMGN). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — AMGN
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Reportable Segment $8.15B 100.0% $9.18B 100.0% $8.62B 100.0% $10.05B 100.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?